Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
Friday, March 11, 2011 1:27:42 AM
Dr. Menon and his teams took the pemetrexed discovery studies from Princeton to the human use form now called Alimta. How one can ignore that the raw active ingredient drug is not the same as the approved modified and buffered drug is beyond rational thinking.
Again, Dr. Menon has a Ph.D. in Pharmacology from Harvard. Period. Dr. Menon is a certified Toxicologist. Period. Dr. Menon is a Doctor of Veterinary Medicine. Period. Dr. Menon was the team leader for the animal studies that took the raw compound referred to as Pemetrexed through a process of discovery to the human drug Alimta. Period. He and his team invented Alimta from the base drug Pemetrexed.
Here are 3 free articles listed in PubMed. These 3 are out of a total 34 articles listed in PubMed with Teicher and Menon as authors; both of whom were team leaders. Please also note that the most recent article is 2009, meaning none of those team members would have worked with him if he lied about any qualifications or any aspects of projects he conducted with Teicher, including their joint role in the development of Alimta. Teicher and Menon published Alimta trials up to and including Phase 3 studies. Furthermore, Menon's publications are cited in dozens and dozens of studies using his work as foundational information. None of this would be the case if allegations of exaggeration or lying about credentials had any merit whatsoever.
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M, Palumbo A, Boccadoro M, Anderson KC, Iacobelli M, Richardson PG.
Clin Cancer Res. 2009 Feb 15;15(4):1210-21.
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M.
Clin Cancer Res. 2001 Mar;7(3):634-40.
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG, Amsrud T.
Clin Cancer Res. 2000 Mar;6(3):1016-23.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM